The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Disease Areas
Poster
Quizartinib
ACoP16 | October 18-21, 2025
Hematology
Exposure-overall survival analysis for quizartinib in newly diagnosed patients with FMS-like tyrosine kinase 3-internal-tandem-duplication-positive acute myeloid leukemia
Giovanni Smania
View presentation
Poster
Quizartinib
ACCP 2025 | September 14-16, 2025
Hematology
Impact of concomitant metamizole on quizartinib exposure in QuANTUM-First study
Kyoin Koo
View presentation
Poster
Quizartinib
ACoP16 | October 18-21, 2025
Hematology
Physiologically based pharmacokinetic modeling of quizartinib to assess drug-drug interaction as an inhibitor of breast cancer resistance protein
Akiko Watanabe
View presentation
Poster
Quizartinib
EHA 2026 | June 11 - 14, 2026
Hematology
Quality-adjusted time without symptoms or toxicity of quizartinib vs placebo in patients with newly diagnosed FLT3-ITD+ acute myeloid leukemia in the QuANTUM-First trial
Jorge Cortes
View presentation
Oral
Quizartinib
ASCO 2026 | May 29 - June 2, 2026
Hematology
Quizartinib in combination with decitabine and venetoclax in FLT3-ITD mutated AML
Musa Yilmaz
View presentation
Poster
Quizartinib
EHA 2026 | June 11 - 14, 2026
Hematology
Quizartinib with reinduction chemotherapy and as single-agent maintenance in children and adolescents with relapsed/refractory FLT3-ITD+ AML: A phase 1/2 multicenter study
C. Michel Zwaan
View presentation
Mini-Oral
Quizartinib
EHA 2025 | June 12-15, 2025
Hematology
The combination of an FLT3-ITD, NPM1mut, and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trial
Mark J. Levis
View presentation
Connect with an MSL
Linkedin Icon Twitter Icon

©2026  Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24